Apixaban
- Generic Name
- Apixaban
- Brand Names
- Eliquis, Apixaban Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N5O4
- CAS Number
- 503612-47-3
- Unique Ingredient Identifier
- 3Z9Y7UWC1J
- Background
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.
- Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism
- Associated Therapies
- -
Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 101
- Registration Number
- NCT02565693
- Locations
- 🇳🇱
Haaglanden MC, Den Haag, Netherlands
🇳🇱Leiden University Medical Center, Leiden, Netherlands
🇳🇱Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 72
- Registration Number
- NCT02559856
- Locations
- 🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada
🇨🇦The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada
🇨🇦University of Alberta, Edmonton, Alberta, Canada
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 229
- Registration Number
- NCT02464969
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸Loma Linda University Cancer Center, Loma Linda, California, United States
🇺🇸UF Health Shands Hospital, Gainesville, Florida, United States
Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot Study
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT02450682
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Apixaban for Treatment of Embolic Stroke of Undetermined Source
- Conditions
- Interventions
- First Posted Date
- 2015-04-27
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 352
- Registration Number
- NCT02427126
- Locations
- 🇩🇪
Regiomed Kliniken Coburg GmbH Abt. II, Coburg, Germany
🇩🇪Neurologie, Klinikum Friedrichshafen GmbH, Friedrichshafen, Germany
🇩🇪Carl von Basedow KlinikumSaalekreis gGmbH, Merseburg, Germany
A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
- Conditions
- Interventions
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 4614
- Registration Number
- NCT02415400
- Locations
- 🇺🇸
Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States
🇺🇸Southern Arizona VA Health Care System, Tucson, Arizona, United States
🇺🇸Saint Lukes Idaho Cardiology Associates, Boise, Idaho, United States
Apixaban Pharmacokinetics in Bariatric Patients (APB)
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 33
- Registration Number
- NCT02406885
- Locations
- 🇺🇸
The Johns Hopkins Center for Bariatric Surgery, Baltimore, Maryland, United States
Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli
- Conditions
- Interventions
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT02378623
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
- Conditions
- Interventions
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 512
- Registration Number
- NCT02369653
- Locations
- 🇺🇸
Sinai Hospital Of Baltimore, Baltimore, Maryland, United States
🇺🇸University Hospitals, Cleveland, Ohio, United States
🇺🇸Children'S Center For Cancer And Blood Diseases, Indianapolis, Indiana, United States
Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100
- Registration Number
- NCT02345343
- Locations
- 🇲🇽
Local Institution, Queretaro, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.